v3.26.1
Acquisitions and Licensing Arrangements - Narrative (Details)
$ in Millions
1 Months Ended 3 Months Ended
Feb. 24, 2026
USD ($)
Jan. 31, 2026
USD ($)
employee
Mar. 31, 2026
USD ($)
Mar. 31, 2025
USD ($)
Asset Acquisition [Line Items]        
Proceeds from sale of Jada     $ 433.0 $ 0.0
Gain on disposition of business     81.0 $ 0.0
Disposal Group, Not Discontinued Operations | Jada        
Asset Acquisition [Line Items]        
Consideration   $ 465.0    
Proceeds from sale of Jada   440.0    
Potential earnout payments   $ 25.0    
Number of employees transferred | employee   100    
Gain on disposition of business     81.0  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Shanghai Henlius Biotech, Inc.        
Asset Acquisition [Line Items]        
Payables in relation to license agreement     17.0  
Payables in relation to license agreement, first installment     10.0  
Payables in relation to license agreement, second installment     7.0  
Currently marketed products - products and product right     $ 17.0  
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Sebela Pharmaceutical        
Asset Acquisition [Line Items]        
Payment towards amount in connection with license agreement $ 27.5      
Potential milestone payments $ 505.0